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Abstract 
Objective: To assess in vivo the expression of phosphodiesterase 4 (PDE4) and its 
relevance to cognitive symptoms in Parkinson’s disease (PD) patients using 
[11C]rolipram PET molecular imaging. 
Methods: We studied 12 levodopa-treated PD patients with no concurrent diagnosis 
of mild cognitive impairment or dementia. Their data were compared to those from 12 
healthy controls. All participants underwent cognitive assessment using the 
Cambridge Neuropsychological Test Automated Battery (CANTAB®).  Parametric 
images of [11C]rolipram volume of distribution (VT) values were determined with the 
Logan plot. 
Results: PD patients performed worse than healthy controls in cognitive 
examinations assessing psychomotor speed, episodic memory, and spatial working 
memory and executive function. PD patients showed reductions in [11C]rolipram VT 
compared to healthy controls, in the caudate (28%), thalamus (23%), hypothalamus 
(32%) and in the cortex (16%). Within thalamic sub-regions [11C]rolipram VT values 
in PD patients were decreased by 12-32% with most marked decreases observed in 
prefrontal and temporal thalamic nuclei whereas motor nuclei were the less affected. 
Within the cortex [11C]rolipram VT values in PD patients were decreased by 11-20% 
with most marked decreases observed in posterior dorsolateral frontal cortex, medial 
frontal cortex and supplementary motor area, whereas orbitofrontal cortex was less 
affected. Worse performance in spatial working memory correlated with lower 
[11C]rolipram VT values in posterior dorsolateral frontal cortex, medial frontal cortex, 
supplementary motor area, precentral gyrus, caudate, and prefrontal thalamic nuclei. 
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Conclusions: Our findings demonstrate loss of PDE4 expression in the striato-
thalamo-cortical circuit, which is associated with deficits of spatial working memory 
in PD patients. 
 
Introduction 
Patients with Parkinson’s disease (PD) carry a six-fold increased risk of developing 
dementia compared to the general population, and it is estimated that up to 80% of PD 
patients will develop cognitive impairment over the course of their illness (1). Deficits 
in executive functions can occur early in de-novo patients with PD without a formal 
diagnosis of cognitive impairment or even before the development of overt motor 
symptoms (2).   
 
Spatial working memory is an executive function that typically is impaired early in 
the course of PD (3, 4). The Parkinson Associated Risk Syndrome (PARS) study has 
shown impaired working memory in individuals at risk for developing PD suggesting 
that these subdomain cognitive deficits may be part of the PD premotor stage (5). 
 
Phosphodiesterase 4 (PDE4) is an intracellular enzyme widely expressed in neurons 
and glial cells, where it hydrolyses cyclic adenosine monophosphate (cAMP) (6, 7). 
PDE4 regulates the cAMP–protein kinase A (PKA)–cAMP response element binding 
protein (CREB) pathway, and modulates the transcription of proteins involved in 
synaptic plasticity and memory process (8). Aberrant and sustained activation of 
cAMP/PKA signalling can lead to long-lasting plasticity and memory deficits (9). 
Disinhibition of cAMP/PKA signalling occurs in the prefrontal cortex of aged rats 
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and monkeys with working memory deficits suggesting a key role of cAMP/PKA 
pathways in the modulation of executive dysfunction (9). 
 
Different lines of evidence in experimental animals confirm a clear role for PDE4 in 
modulating cognition, including working memory. PDE4 knockout mice show 
enhanced long-term depression and impaired long-term memory in a fear-
conditioning paradigm (10), and impaired spatial working memory (11). Reduced 
PDE4 protein levels in the hippocampus along with hyperactivity of the PKA 
pathway has been associated with cognitive decline in a rodent model of Huntington’s 
disease (12). In mice, intraperitoneal administration of the PDE-4 inhibitor rolipram 
enhanced spatial working memory consolidation in the Morris water maze task (13). 
In rodents, rolipram has been shown to improve working memory deficits caused by 
administration of scopolamine, a muscarinic receptor antagonist (14) and MK-801, a 
NMDA antagonist (15). Treatment with PDE4 inhibitors also ameliorated spatial 
working memory deficits in transgenic mouse model of Alzheimer’s disease (16).  
 
Here, we investigated in vivo the expression of PDE4 and its relevance to cognitive 
deficits in PD patients, using PET with [11C]rolipram, which is a selective PDE4 
radioligand for human use (17).   
 
Age-related reduction of PDE4 has been previously reported in vitro in the cortical 
regions of rodents (18) and in vivo in the striatum and frontal cortex of non-human 
primates (19). However, in humans a [11C]rolipram PET study has shown that age 
does not affect PDE4 expression in cortical and subcortical regions of  healthy 
controls and patients with major depressive disorder between 18 to 55 years of age 
(20). As age-related reduction in PDE4 expression in healthy people older than 55 
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years old has not been investigated, we also explored the influence of age in our 
cohort of healthy controls. 
 
Our findings suggest loss of PDE4 expression in striato-thalamo-cortical network in 
patients with PD, which is associated with working memory deficits. 
 
Materials and methods 
Participants and clinical characteristics  
Twelve patients with a diagnosis of idiopathic PD according to the Queen Square 
Brain Bank criteria were recruited from specialist Movement Disorders clinics at the 
National Hospital of Neurology & Neurosurgery, Queen Square, London (Table 1). 
None of these patients fulfilled the diagnostic criteria of PD mild cognitive 
impairment or PD dementia (21, 22).  
 
Twelve healthy individuals with no history of neurological or psychiatric disorders 
served as the control group. To assess the effect of age on PDE4 expression, we 
studied a younger (n=6; 5 males; mean age ±SD=39.0±8.4; age range=26-52 years 
old) and an older (n=6; 5 males; mean age ±SD= 66.3±3.6; age range=53-78 years 
old) subgroup of healthy controls.   
 
All participants screened successfully to undertake PET and MRI scanning under 
scanning safety criteria (http://www.mrisafety.com; 
https://www.gov.uk/government/publications/arsac-notes-for-guidance), had no 
history of other neurological or psychiatric disorders, and were not under treatment 
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with substances with known actions in PDEs (e.g. apremilast, cilomilast, luteolin, 
piclamilast, roflumilast and ibudilast).  
 
PD patients were all on levodopa treatment. Daily and lifetime dopaminergic 
medication dose was calculated with a formula based on the theoretical equivalence to 
levodopa (23). Motor symptom severity was assessed with the Unified PD Rating 
Scale part-III (UPDRS-III) and according to Hoehn & Yahr stage. Motor assessments 
were performed OFF medication after overnight withdrawal of patient’s dopaminergic 
medications, and also following a challenge with levodopa 250/carbidopa 25, with an 
observational ON-medication period of 150 min. Neuropsychiatric symptoms were 
assessed with the Apathy Evaluation Scale, Beck Depression Inventory-II (BDI-II), 
and the Hamilton Depression Rating Scale (HDRS). Non-motor Symptoms Scale for 
PD was used to assess non-motor symptoms. The Mini Mental Status Examination 
(MMSE) and Montreal Cognitive Assessment (MoCA) were used to assess general 
cognitive status. Further cognitive assessments were carried out using the Cambridge 
Neuropsychological Test Automated Battery (CANTAB®) and included assessments 
related to psychomotor speed (Reaction Time), attention (Rapid Visual Information 
Processing), episodic memory (Paired Associate Learning and Delayed Match to 
Sample), working memory and executive function (Spatial Working Memory). 
CANTAB® neuropsychological tests have been previously described in detail (24) and 
shown to be highly sensitive to deterioration in executive function in PD (25). Quality 
of life was measured with the patient self-reported 39-item PD Questionnaire (PDQ-
39). 
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The study was approved by the institutional review boards and the research ethics 
committee. Written informed consent was obtained from all study participants in 
accordance with the Declaration of Helsinki. 
 
Imaging data analysis 
MRI-based volumetric analysis 
Since PDE4 is an intracellular enzyme, neuronal loss may affect PDE4 availability as 
measured with PET.  We investigated volumetric changes in cortical and subcortical 
nuclei regions in our cohort of PD patients compared to healthy controls. We used the 
FreeSurfer image analysis suite (version 5.3.0 http://surfer.nmr.mgh.harvard.edu) to 
process individual MRI scans, to derive measures of cortical thickness and subcortical 
nuclei volumes (Supplemental methods).  
 
[11C]rolipram PET data analysis 
Image processing and kinetic modelling was carried out using the Molecular Imaging 
and Kinetic Analysis Toolbox software package (MIAKATTM: www.miakat.org; 26), 
implemented in MATLAB® (The Mathworks, Natick, MA, USA). MIAKAT™ 
combines in-house code with wrappers for FMRIB Software Library (FSL, 
http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and Statistical Parametric Mapping (SPM, 
http://www.fil.ion.ucl.ac.uk/spm/) commands in order to provide state-of-the-art 
functionality within a coherent analysis framework. The MIAKATTM processing 
pipeline was followed, ensuring that all quality control steps were completed to 
generate both parametric images and regional estimates of [11C]rolipram volume of 
distribution (VT). 
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Appropriate and individualised brain extraction fractional intensity threshold was 
selected and applied to the individual isotopic MRI, using the FSL Brain Extraction 
Tool. The T1-weighted MR image was segmented into white matter, grey matter and 
cerebrospinal fluid. Normalisation of the T1 MR image into stereotaxic space enabled 
non-linear registration between template brain MRI [Montreal Neurological Institute 
(MNI)-152 template], stereotaxic neuroanatomical CIC atlas version 2.0 (27), and the 
individual subject.  
Individual PET frames were corrected for head motion using frame-by-frame rigid 
registration using a frame with high signal-to-noise ratio as reference. PET images 
were co-registered to the corresponding MPRAGE MRI.  
Parent in plasma input function were generated using the continuous and discrete 
blood samples. Parent fraction was modelled using the Hill model (28). Parametric 
images of [11C]rolipram VT values were calculated with the Logan plot (29) which 
provides more accurate [11C]rolipram VT values than those obtained with 
compartmental models (30). The anatomical CIC atlas version 2.0 (27) was used to 
define regions of interest (ROIs).   
 
Statistical analysis 
Statistical analysis and graph illustration were performed with SPSS (version 20 
Chicago, Illinois, USA) and GraphPad Prism (version 6.0c) for MAC OS X, 
respectively. For all variables, variance homogeneity and Gaussianity were tested 
with Bartlett and Kolmogorov-Smirnov tests. Multivariate analysis of variance 
(MANOVA) was used to assess the main effects of regional [11C]rolipram VT 
between PD patients and healthy controls. If the overall multivariate test was 
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significant, P values for each variable were calculated following Benjamini-Hochberg 
multiple-comparisons test in order to reduce false discovery rate. We set the false 
discovery rate cut-off at 0.05. We interrogated correlations between PET and clinical 
data using Spearman’s r correlation coefficient and we applied the Benjamini-
Hochberg correction. All data are presented as mean±SD, and the level α was set for 
all comparisons at P<0.05, Benjamini-Hochberg corrected.  
 
Results 
Cognitive and neuropsychiatric function 
PD patients performed worse than healthy controls in the assessments of psychomotor 
speed [five choice median reaction time (Puncor=0.014; Padj=0.012) and median 
movement time (Puncor<0.001; Padj<0.001)], episodic memory [delayed match to 
sample % correct (Puncor=0.003; Padj=0.006)], and working memory and executive 
function [spatial working memory between errors (Puncor=0.016; Padj=0.031)] 
(Supplemental Table 1).  
Neuropsychiatric assessments showed significant differences between healthy 
controls and PD patients (BDI-II: P<0.05; HDRS: P<0.05); however, the 
neuropsychiatric burden in our cohort of PD patients was minimal and did not meet 
the cut-off score for depression. 
 
Volumetric analysis 
Freesurfer analysis showed no volumetric differences in cortical and subcortical 
nuclei ROIs between the groups of PD patients and healthy controls (Supplemental 
Table 2). Moreover, no significant associations were observed between cortical and 
 11 
subcortical volumes and [11C]rolipram
 
VT for the whole brain analysis in the group of 
healthy controls (P>0.10 for all brain regions). 
 
 
Effect of age on PDE4 expression 
We found no significant differences in cortical and subcortical nuclei [11C]rolipram
 
VT between the group of younger and older healthy control subgroups (all P>0.10; 
Supplemental Table 3). Moreover, in the group of healthy controls there were no 
significant associations between age and [11C]rolipram
 
VT for any brain region 
(P>0.18 for all brain regions). 
 
Effect of medication on PDE4 expression 
We did not find any interactions between daily and lifetime levodopa equivalent dose 
measured in total or for levodopa or dopamine agonist medications separately, and 
[11C]rolipram
 
VT  in all the regions of interested examined (P>0.10). 
 
 
PDE4 expression in Parkinson’s patients 
 
We found 5-32% decreases in [11C]rolipram
 
VT in PD patients compared to the group 
of healthy controls. PD patients had significantly lower mean [11C]rolipram
 
VT in 
subcortical nuclei (P=0.018; Table 2; Figures 1A, 2 and 3) and frontal cortex regions 
(P=0.029; Table 2; Figures 1B, 2 and 3). Although the general trend was for lower 
[11C]rolipram
 
VT in all cortical regions, there were no significant differences in 
[11C]rolipram
 
VT between the patients with PD and healthy controls in parietal, 
temporal and occipital cortices (all P>0.10). 
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PD patients had significantly lower mean [11C]rolipram
 
VT in the caudate, accumbens, 
thalamus and hypothalamus compared to healthy controls, with no significant changes 
observed in putamen, globus pallidus and  substantia nigra  (Table 2; Figures 1A, 2 
and 3). Within the thalamus, loss of [11C]rolipram
 
VT was driven by prefrontal, 
temporal, posterior parietal and primary sensory thalamic nuclei, with no significant 
changes in motor thalamic nuclei in PD patients compared to healthy controls (Table 
2; Figures 1A, 2 and 3).  
 
In the frontal cortex, [11C]rolipram
 
VT was decreased in the precentral gyrus, 
dorsolateral frontal cortex, posterior dorsolateral frontal cortex, medial frontal cortex  
including anterior medial frontal cortex and posterior medial frontal cortex, central 
and frontal operculum and supplementary motor area (Table 2; Figures 1B, 2 and 3).  
 
Correlations: PDE4 expression and Spatial Working Memory 
In PD patients, higher number of errors in the spatial working memory test was 
associated with lower [11C]rolipram VT in the precentral gyrus (rs=−0.59; 
Puncor=0.035; Padj=0.045), posterior dorsolateral frontal cortex (rs=−0.62; 
Puncor=0.032; Padj=0.045), medial frontal cortex (rs=−0.63; Puncor=0.030; Padj=0.045), 
posterior medial frontal cortex (rs=−0.74; Puncor=0.006; Padj=0.036), supplementary 
motor area (rs=−0.69; Puncor=0.012; Padj=0.036), caudate (rs=−0.60; Puncor=0.035; 
Padj=0.045), precommissural caudate (rs=−0.70; Puncor=0.011; Padj=0.036), and 
prefrontal thalamic nuclei (rs=−0.60; Puncor=0.039; Padj=0.045) (Figure 1C). We did 
not find any correlations between frontal cortex nor subcortical nuclei [11C]rolipram 
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VT and motor, neuropsychiatric and cognitive measures of psychomotor speed and 
episodic memory (all P>0.10). 
 
Discussion 
Using [11C]rolipram PET molecular imaging in vivo, we report for the first time loss 
of PDE4 expression within the striato-thalamo-cortical brain circuitry of PD patients, 
which is associated with spatial working memory deficits. Our findings demonstrate 
16-32% loss of PDE4 expression in the striatum, thalamus, hypothalamus and frontal 
cortex of PD patients who had episodic and working memory deficits, were on 
dopamine-replacement therapy, but had no significant brain atrophy in the regions of 
interest examined.  
 
PDE4 expression was decreased by 12-32% within the thalamus with most marked 
decreases observed in prefrontal and temporal lobe-projecting thalamic nuclei, 
whereas motor nuclei were less affected. Within the cortex PDE4 expression in PD 
patients were decreased by 11-20% with most marked decreases observed in the 
posterior dorsolateral frontal cortex, medial frontal cortex and supplementary motor 
area, whereas the orbitofrontal cortex and frontal operculum were the least affected.  
 
There are no previous clinical or preclinical studies investigating the expression of 
PDE4 in PD. Studies in PDE4 knockout mice have demonstrated impaired spatial 
working memory (11). In animal models of Huntington’s disease, decreased PDE4 
protein levels and PKA hyper-activation in the hippocampus were associated with 
spatial memory deficits, suggesting that PDE4-dependent regulation of cAMP/PKA 
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signalling cascade may be one molecular mechanism underlying cognitive decline 
(12).  
 
In this study we found significant associations between loss of PDE4 expression in 
the caudate, thalamic nuclei and frontal cortices, and spatial working memory deficits 
in PD patients. The striato-thalamo-cortical circuit has been closely linked to spatial 
working memory. The dorsolateral prefrontal cortex is part of the network mediating 
spatial working memory processes (31). The medial frontal cortex plays an important 
role in performance monitoring on subsequent trials and in the implementation of 
associated adjustments in cognitive control (32). Neuroimaging studies have shown a 
close interaction between the posterior medial frontal cortex and dorsolateral 
prefrontal cortex (32). While the posterior medial frontal cortex controls for errors 
and sends the signal for adjustments, the dorsolateral prefrontal cortex in turn 
implements the necessary top-down control (32). This functional interplay is also 
mediated by the supplementary motor area, which plays a role in spatial rehearsal 
(33), and other subcortical structures such as the caudate and thalamic nuclei. Within 
the caudate, the precommisural dorsal caudate is the area of the striatum that receives 
the largest corticostriatal projections from the dorsolateral prefrontal cortex and is 
involved in spatial memory processes (34). Output from the basal ganglia projects to 
the thalamus which closes the circuit by projecting back to the dorsolateral frontal 
cortex (35). Our findings show that, within the thalamus, loss of PDE4 expression 
only in the subregions connected to the prefrontal cortex is associated with spatial 
working memory deficits in patients with PD. 
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Cognitive impairment is a very common feature of PD, affecting up to 57% of 
patients within the first 3–5 years after PD diagnosis, and adds significantly to 
patients and carers’ burden (36). Spatial working memory is affected early in the 
course of the disease and may represent one of the pre-motor symptoms of PD. 
Recent evidence has shown that healthy subjects over the age of 50 who are at risk of 
developing PD (exhibiting hyposmia and dopamine transporter reduction) performed 
worse at cognitive tests assessing spatial working memory (5). Previous functional 
MR and H215O PET molecular imaging studies have shown that blood flow is reduced 
in the fronto-striatal circuit while performing working memory tasks in PD patients 
with and without cognitive impairment (4, 37, 38). In agreement with these findings, 
we found significant correlations between worse performance in the spatial working 
memory tests and decreases in PDE4 expression in precentral gyrus, dorsolateral 
prefrontal cortex, medial frontal cortex and precommisural dorsal caudate. 
 
We have recently shown that another PDE, PDE10A, is decreased by 14–28% in the 
striatum and pallidum of moderate/advanced PD patients and loss of PDE10A 
expression is associated with the severity of motor symptoms and complications (39). 
In comparison with PDE10A, which is mainly expressed in the basal ganglia, PDE4 is 
widely expressed in the cortex and subcortical regions intimately involved in 
cognitive processes (7). Hereby, it is not surprising that we did not find significant 
decreases in PDE4 expression in subcortical nuclei specifically involved in the control 
of movement such as putamen and pallidum. Taking together our previous and recent 
findings, it is likely that while PDE10A plays a role in the control of movement, 
PDE4 is involved in the regulation of cognitive processes and both enzymes are 
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decreased in PD patients leading to the manifestation of motor and cognitive 
symptoms.  
 
The PDE4 family is comprised of four isoforms: PDE4A, B, C and D which encode 
for distinct proteins (40). Preclinical studies have shown that distinct subtypes of 
PDE4 isoforms differentially modulate synaptic activity and have distinct 
neurological role (10, 11). PDE4B modulates long-term depression and loss of this 
isoform causes impaired spatial working memory (11), whereas PDE4D regulates 
long-term potentiation and loss of this isoform leads to impaired fear conditioning in 
mice (10). [11C]rolipram binds with high affinity to all four PDE4 isoforms (17), thus 
it was not possible to investigate in humans the different role of PDE4 subtypes. 
 
In our study we also investigated the effect of age on PDE4 expression in a cohort of 
healthy controls. Preclinical studies have shown age-related reduction of PDE4 
expression in the striatum and cortex of rodents and non-human primates (18, 19). In 
the striatal and cortical brain tissue of aged rats (100 week old), [3H]rolipram binding 
was decreased by 58-69% compared to young rats (10 week old) (18), and 
[11C]rolipram binding was decreased by 20-25% in the striatum and frontal cortex of 
aged monkeys (19).  However, more recent work indicated that age does not affect 
[11C]rolipram VT in cortical and subcortical regions of healthy controls and patients 
with major depressive disorder aged between 18 to 55 years old (20). Our findings are 
in agreement with the previous study in humans, and we report no age-related 
reduction in cortical and subcortical PDE4 expression in healthy controls spanning 
between 26 to 78 years of age.  
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In conclusion, our findings provide evidence for a novel neurochemical change in PD, 
which is linked with working memory deficits. PDE4 could serve as a novel 
therapeutic target for manipulation with pharmacotherapy, and PDE4 modulating 
drugs could potentially have a therapeutic role in the alleviation of cognitive 
symptoms in PD. 
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FIGURE LEGENDS 
Fig. 1 PDE4 expression in the groups of Parkinson’s disease patients and healthy 
controls. Column bar graphs showing mean [11C]rolipram volume of distribution (VT) 
in (A) subcortical and (B) cortical brain regions between PD patients and healthy 
controls. (C) Correlations between loss of PDE4 expression and spatial working 
memory deficits in patients with PD. Higher number of errors at the spatial working 
memory test was associated with lower [11C]rolipram VT in precentral gyrus, posterior 
dorsolateral frontal cortex, medial frontal cortex, posterior medial frontal cortex, 
supplementary motor area, caudate, precommissural caudate, and prefrontal thalamic 
nuclei. Colour bar reflects range of [11C]rolipram VT intensity. Error bars represent 
mean ± SD. *P<0.05. All P values are Benjamini-Hochberg corrected for multiple 
comparisons.  
 
Fig. 2 Mean cortical and subcortical loss of PDE4 expression in Parkinson’s disease 
patients. Axial, coronal and sagittal (MNI co-ordinates: x = 19, y = −8, z = 4) mean 
summed [11C]rolipram PET images derived from (A) 12 healthy controls and (B) 12 
PD patients in stereotaxic space showing significant loss of [11C]rolipram volume of 
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distribution (VT) in the PD patients. Colour bar reflects range of [11C]rolipram VT 
intensity. 
 
Fig. 3 Cortical and subcortical loss of PDE4 expression in a Parkinson’s disease 
patient. Axial summed [11C]rolipram PET images for (A) a 69 year-old healthy 
female (MMSE: 30; MoCA: 30; SWM errors: 8) and (B) a  72 year-old female  with a 
seven years history of PD (H&Y: 2; UPDRS-III: 37; MMSE: 27; MoCA: 29; SWM 
errors: 26). Colour bar reflects range of [11C]rolipram volume of distribution (VT) 
intensity. 
 
TABLES 
Table 1 Clinical characteristics of Parkinson’s disease patients 
Subject Sex Age 
(years) 
Disease 
duration1 
PD 
medication 
duration 
(years) 
Daily 
LED 
(mg)2 
Hoehn 
and 
Yahr 
PDQ-
39 
1 M 73.0 9 7.0 605 3 56 
2 F 68.8 7 0.9 560 3 18 
3 F 58.5 3 12.0 150 1 6 
4 M 76.8 7 5.0 150 2 14 
5 M 73.3 10 9.0 400 3 36 
6 M 76.5 9 7.0 1229 2 15 
7 F 80.0 25 21.0 1383 4 75 
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8 F 72.6 7 5.0 640 2 55 
9 M 73.4 17 13.0 4236 4 37 
10 M 74.6 13 11.0 730 2 9 
11 M 70.5 10 9.0 4149.5 4 44 
12 F 54.1 18 15.0 797 2.5 48 
Mean 
±SD 
7M/
5F 
71.0 
(±7.5) 
11.25 
(±6.1) 
9.58  
(±5.3) 
1252.46 
(±1421) 
2.71 
(±1.0) 
34.42 
(±22) 
1From time of first appearance of PD motor symptoms; 2LED: Levodopa Equivalent Dose. 
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Table 2 Subcortical nuclei and frontal cortices [11C]rolipram VT in the groups of 
Parkinson’s disease patients and healthy controls. 
 A-ROIs1 Healthy 
Controls 
PD patients P value 
uncorr 
P 
value* 
% 
change 
in PD 
Subcortical 
Striatum (mean±SD) 0.85 (±0.10) 0.70 (±0.18) 0.0194 0.035 −17.7% 
 
Caudate (mean±SD) 0.71 (±0.07) 0.51 (±0.20) 0.0036 0.020 −27.8% 
Precommissural 
Caudate (mean±SD) 
0.74 (±0.08) 0.54 (±0.19) 0.0029 0.020 −27.2% 
Postcommissural 
Caudate (mean±SD) 
0.65 (±0.08) 0.49 (±0.20) 0.0185 0.035 −24.8% 
Putamen (mean±SD) 0.92 (±0.12) 0.82 (±0.19) >0.10 >0.10 −11.3% 
Precommissural 
Putamen (mean±SD) 
0.97 (±0.13) 0.85 (±0.21) >0.10 >0.10 −11.9% 
Postcommissural 
Putamen (mean±SD) 
0.90 (±0.12) 0.79 (±0.19) >0.10 >0.10 −12.2% 
Accumbens 
(mean±SD) 
0.89 (±0.13) 0.73 (±0.17) 0.0187 0.035 −17.5% 
Globus Pallidus 
(mean±SD) 
0.87 (±0.15) 0.76 (±0.18) >0.10 >0.10 −12.5% 
Thalamus (mean±SD) 0.78 (±0.09) 0.60 (±0.16) 0.0037 0.013 −22.8% 
Thalamus primary 
motor (mean±SD) 
0.85 (±0.16) 0.72 (±0.16) >0.10 >0.10 −12.3% 
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Thalamus primary 
sensory (mean±SD) 
0.84 (±0.08) 0.72 (±0.16) 0.0257 0.043 −15.2% 
Thalamus prefrontal 
(mean±SD) 
0.81 (±0.11) 0.63 (±0.17) 0.005 0.013 −22.4% 
Thalamus posterior 
parietal (mean±SD) 
0.82 (±0.09) 0.69 (±0.18) 0.0272 0.043 −16.5% 
Thalamus temporal 
(mean±SD) 
0.68 (±0.08) 0.46 (±0.18) 0.0008 0.006 −32.0% 
Thalamus occipital 
(mean±SD) 
0.80 (±0.08) 0.65 (±0.19) >0.10 >0.10 −19.2% 
Hypothalamus 
(mean±SD) 
0.77 (±0.26) 0.53 (±0.17) 0.0192 0.035 −31.8% 
Substantia Nigra 
(mean±SD) 
0.67 (±0.23) 0.52 (±0.15) >0.10 >0.10 −14.6% 
Frontal cortices 
Precentral gyrus 
(mean±SD) 
0.74 (±0.10) 0.62 (±0.15) 0.026 0.043 −16.4% 
 
DLFC (mean±SD) 0.77 (±0.09) 0.64 (±0.15) 0.026 0.043 −15.9% 
Anterior DLFC 
(mean±SD) 
0.77 (±0.09) 0.66 (±0.15) >0.10 >0.10 −14.4% 
Posterior DLFC 
(mean±SD) 
0.78 (±0.10) 
0.63 (±0.17) 0.019 0.043 −20.0% 
MFC (mean±SD) 0.77 (±0.10) 0.62 (±0.15) 0.012 0.043 −18.7% 
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Anterior MFC 
(mean±SD) 
0.76 (±0.10) 0.63 (±0.14) 0.015 0.043 −11.9% 
Posterior MFC 
(mean±SD) 
0.78 (±0.10) 0.63 (±0.17) 0.012 0.043 −20.0% 
Frontal Operculum 
(mean±SD) 
0.84 (±0.12) 0.70 (±0.16) 0.029 0.043 −13.6% 
Central Operculum 
(mean±SD) 
0.83 (±0.11) 0.69 (±0.16) 0.021 0.043 −17.1% 
OFC (mean±SD) 0.85 (±0.11) 0.74 (±0.16) 0.067 >0.10 −12.9% 
Medial OFC 
(mean±SD) 
0.86 (±0.11) 0.77 (±0.17) >0.10 >0.10 −10.5% 
Lateral OFC 
(mean±SD) 
0.84 (±0.12) 
0.72 (±0.16) >0.10 >0.10 −14.5% 
SMA 0.76 (±0.11) 0.63 (±0.15) 0.023 0.023 −17.6% 
1A-ROIs: anatomical regions of interest. *P values are Benjamini-Hochberg corrected for 
multiple comparisons. DLFC=dorsolateral frontal cortex; MFC=medial frontal cortex; 
OFC=orbitofrontal cortex; SMA=supplementary motor area. 
 
 



